Format

Send to

Choose Destination
Contraception. 2012 May;85(5):453-7. doi: 10.1016/j.contraception.2011.09.015. Epub 2011 Nov 12.

Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.

Author information

1
Planned Parenthood of Southwest and Central Florida, Sarasota, FL 34236, USA. suzie.prabhakaran@myplannedparenthood.org

Abstract

BACKGROUND:

The objectives of the study were to assess feasibility, continuation rates and patient satisfaction with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).

MATERIALS AND METHODS:

The study included 50 DMPA-seeking women between the ages of 18 and 49 years enrolled at two Florida Planned Parenthood health centers. Participants were taught self-injection during their initial study visit and, upon proficiency, self-injected one dose in clinic. Participants then injected a series of three more doses outside the health center over 9 months. Continuation rates, feasibility and acceptability were determined by analysis of four postinjection surveys.

RESULTS:

Continuation of DMPA-SC at injection 4 was 74% (95% confidence interval 62%-86%). Overall, survey responses from the three at-home injections indicated the method to be convenient (95%), easy (87%) and recommendable to others (94%). Twenty percent of injections were met with difficulty, most commonly cited as plunger resistance. No pregnancies occurred in study.

CONCLUSIONS:

Continuation was high with DMPA-SC self-injection. Participants reported injection to be easy and convenient and are likely to recommend self-administration to other women. Device issues are one potential deterrent.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center